Medications that were originally used to treat depression and epilepsy can help patients with chronic nerve pain
Public awareness of GLP-1 medications reached unprecedented levels following tirzepatides approval
Therefore, semaglutide could improve other obesity-related pathologies like cardiovascular, hypertension, or fatty liver diseases
Healthcare providers should assess: Body composition changes (not just weight) to evaluate muscle mass preservation Glycemic control in patients with diabetes, adjusting other medications as needed Thyroid function if symptoms of hypothyroidism develop (fatigue, cold intolerance) Nutritional status through clinical assessment and laboratory testing when indicated Patients experiencing excessive fatigue, cold intolerance, or other symptoms potentially indicating metabolic suppression should be evaluated promptly, though these symptoms more commonly relate to rapid weight loss itself rather than direct drug effects
According to the SmPC, semaglutide has a half-life of approximately one week, and steady-state plasma concentrations are reached after 45 weeks of once-weekly administration
